Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial
Listen to this summary
The study aimed to determine whether adding the bispecific antibody ivonescimab to chemotherapy improves overall survival in patients with EGFR-variant non-small cell lung cancer (NSCLC) who have progressed after prior EGFR tyrosine kinase inhibitor therapy. Results showed that ivonescimab combined with chemotherapy significantly increased median overall survival to 16.8 months compared to 14.1 months with chemotherapy alone, indicating a clinically meaningful benefit despite a higher incidence of treatment-emergent adverse events.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from JAMA
View all →Jun 24, 2026 · JAMA
Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial
Jun 17, 2026 · JAMA
Prone Positioning in Infants With Acute Bronchiolitis: The PROPOSITIS Randomized Clinical Trial
Jun 15, 2026 · JAMA
Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes
Jun 15, 2026 · JAMA
An AI-Based OCT System to Detect Diabetic Macular Edema: A Prospective Validation and Noninferiority Randomized Clinical Trial
Jun 15, 2026 · JAMA
Low Back Pain: A Review
Jun 12, 2026 · JAMA
Gastric Residual Volume Assessment in Critically Ill Children: The GASTRIC-PICU Randomized Clinical Trial
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
